Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 6, 2010, Pages 1228-1236

  Baudoux, Pierre ^a   Lemaire, Sandrine ^a   Denis, Olivier ^b   Tulkens, Paul M ^a   Van Bambeke, Françoise ^a   Glupczynski, Youri ^c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

Cfr; Erm(A B); Maximal relative efficacy; Pharmacodynamics; Relative potency; Static concentration; THP 1 macrophages

Indexed keywords

CLINDAMYCIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; METHIONINE SULFOXIDE REDUCTASE A; METHYLTRANSFERASE; METICILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTIN; RIFAMPICIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; MACROPHAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PH; PHAGOCYTOSIS; PHENOTYPE; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; CELL LINE; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PHAGOCYTOSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRGINIAMYCIN;

EID: 77953520234     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq110     Document Type: Article

References (64)

1. Garzoni C, Kelley WL. Staphylococcus aureus: New evidence for intracellular persistence. Trends Microbiol 2009; 17: 59-65.
2. Van Bambeke F, Barcia-Macay M, Lemaire S et al. Cellular pharmacodynamics and pharmacokinetics of antibiotics: Current views and perspectives. Curr Opin Drug Discov Devel 2006; 9: 218-30.
3. Lina G, Quaglia A, Reverdy ME et al. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999; 43: 1062-6.
4. Schmitz FJ, Verhoef J, Fluit AC. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. Sentry Participants Group. J Antimicrob Chemother 1999; 43: 783-92.
5. Limbago B, Fosheim GE, Schoonover V et al. Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: A population-based analysis. J Clin Microbiol 2009; 47: 1344-51.
6. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7: 327-32.
7. Finks J, Wells E, Dyke TL et al. Vancomycin-resistant Staphylococcus aureus, MI, USA, 2007. Emerg Infect Dis 2009; 15: 943-5.
8. Jones RN, Ross JE, Bell JM et al. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagn Microbiol Infect Dis 2009; 65: 404-13.
9. Fass RJ. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother 1991; 35: 553-9.
10. Champney WS, Tober CL. Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol 2000; 41: 126-35.
11. Cocito C, Di Giambattista M, Nyssen E et al. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997; 39 Suppl A: 7-13.
12. Bouanchaud DH. In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. J Antimicrob Chemother 1992; 30 Suppl A: 95-9.
13. Harms JM, Schlunzen F, Fucini P et al. Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin. BMC Biol 2004; 2:4.
14. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: Nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34: 482-92.
15. Reynolds E, Ross JI, Cove JH. msr(A) and related macrolide/streptogramin resistance determinants: Incomplete transporters? Int J Antimicrob Agents 2003; 22: 228-36.
16. Mukhtar TA, Koteva KP, Hughes DW et al. Vgb from Staphylococcus aureus inactivates streptogramin B antibiotics by an elimination mechanism not hydrolysis. Biochemistry 2001; 40: 8877-86.
17. Ross EM, Kenakin T. Pharmacodynamics: Mechanism of drug action and the relationship between drug concentration and effect. In: Hardman J, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill Medical Publishing Division, 2001; 31-43.
18. Hershberger E, Donabedian S, Konstantinou K et al. Quinupristin- dalfopristin resistance in gram-positive bacteria: Mechanism of resistance and epidemiology. Clin Infect Dis 2004; 38:92-8.
19. Allignet J, el Solh N. Diversity among the gram-positive acetyltransferases inactivating streptogramin A and structurally related compounds and characterization of a new staphylococcal determinant, vatB. Antimicrob Agents Chemother 1995; 39: 2027-36.
20. Allignet J, el Solh N. Characterization of a new staphylococcal gene, vgaB, encoding a putative ABC transporter conferring resistance to streptogramin A and related compounds. Gene 1997; 202: 133-8.
21. Bouanchaud DH. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin. J Antimicrob Chemother 1997; 39 Suppl A: 15-21.
22. Clarebout G, Nativelle E, Bozdogan B et al. Bactericidal activity of quinupristin-dalfopristin against strains of Staphylococcus aureus with the MLSB phenotype of resistance according to the erm gene type. Int J Antimicrob Agents 2004; 24: 444-9.
23. Manfredi R. A re-emerging class of antimicrobial agents: Streptogramins (quinupristin/dalfopristin) in the management of multiresistant gram-positive nosocomial cocci in hospital setting. Mini Rev Med Chem 2005; 5: 1075-81.
24. Desnottes JF, Diallo N. Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages. J Antimicrob Chemother 1992; 30 Suppl A: 107-15.
25. Yamaoka T. The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSA. J Infect Chemother 2007; 13: 141-6.
26. Lemaire S, Kosowska-Shick K, Julian K et al. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis. Clin Microbiol Infect 2008; 14: 766-77.
27. Nguyen HA, Denis O, Vergison A et al. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: Pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. Antimicrob Agents Chemother 2009; 53: 1434-42.
28. Barcia-Macay M, Seral C, Mingeot-Leclercq MP et al. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 2006; 50: 841-51.
29. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP et al. Evaluationof the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 1177-84.
30. Lemaire S, Glupczynski Y, Duval V et al. Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 2289-97.
31. Long KS, Poehlsgaard J, Kehrenberg C et al. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 2006; 50: 2500-5.
32. Toh SM, Xiong L, Arias CA et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007; 64: 1506-14.
33. Arias CA, Vallejo M, Reyes J et al. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J Clin Microbiol 2008; 46: 892-6.
34. Smith LK, Mankin AS. Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. Antimicrob Agents Chemother 2008; 52: 1703-12.
35. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP et al. Activity of three b-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J Antimicrob Chemother 2005; 55: 897-904.
36. Etienne SD, Montay G, Le Liboux A et al. A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J Antimicrob Chemother 1992; 30 Suppl A: 123-31.
37. Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother 2003; 47: 2283-92.
38. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP et al. Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin. Antimicrob Agents Chemother 2007; 51: 1627-32.
39. Jones RN, Ballow CH, Biedenbach DJ et al. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998; 31: 437-51.
40. Sader HS, Jones RN, Ballow CH et al. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: Results from the global SMART (GSMART) surveillance study. Braz J Infect Dis 2001; 5: 21-31.
41. Denis O, Magdalena J, Deplano A et al. Molecular epidemiology of resistance to macrolides-lincosamides-streptogramins in methicillin-resistant Staphylococcus aureus (MRSA) causing bloodstream infections in patients admitted to Belgian hospitals. J Antimicrob Chemother 2002; 50: 755-7.
42. Decousser JW, Pina P, Picot F et al. Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: A French prospective national survey. J Antimicrob Chemother 2003; 51: 1213-22.
43. Denis O, Deplano A, Nonhoff C et al. National surveillance of methicillin-resistant Staphylococcus aureus in Belgian hospitals indicates rapid diversification of epidemic clones. Antimicrob Agents Chemother 2004; 48: 3625-9.
44. Denis O, Deplano A, Nonhoff C et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother 2006; 50: 2680-5.
45. Sader HS, Watters AA, Fritsche TR et al. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis 2007; 7: 29.
46. Loza E, Morosini MI, Pascual A et al. Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006). Enferm Infecc Microbiol Clin 2008; 26: 489-94.
47. Mendes RE, Sader HS, Deshpande L et al. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis 2008; 60: 433-6.
48. Kehrenberg C, Aarestrup FM, Schwarz S. IS21-558 insertion sequences are involved in the mobility of the multiresistance gene cfr. Antimicrob Agents Chemother 2007; 51: 483-7.
49. Kehrenberg C, Cuny C, Strommenger B et al. Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr. Antimicrob Agents Chemother 2009; 53: 779-81.
50. Morales G, Picazo JJ, Baos E et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010; 50: 821-5.
51. Lemaire S, Van Bambeke F, Tulkens PM. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob Agents Chemother 2009; 53: 3734-43.
52. Lemaire S, Bogdanovitch T, Chavez-Bueno S et al. Bactericidal activity of ceragenin CSA-13 against intracellular MSSA, hospital-acquired (HA) and community-acquired (CA) MRSA, and VISA in THP-1 macrophages: Relation to cellular toxicity? In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract A-633, p. 13. American Society for Microbiology, Washington, DC, USA.
53. Carlier MB, Zenebergh A, Tulkens PM. Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J Antimicrob Chemother 1987; 20 Suppl B: 47-56.
54. de Duve C, de Barsy T, Poole B et al. Commentary. Lysosomotropic agents. Biochem Pharmacol 1974; 23: 2495-531.
55. Baudoux P, Bles N, Lemaire S et al. Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J Antimicrob Chemother 2007; 59: 246-53.
56. Lemaire S, Van Bambeke F, Appelbaum PC et al. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): Studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother 2009; 64: 1035-43.
57. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP et al. Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells. Antimicrob Agents Chemother 2007; 51: 2748-57.
58. Garzoni C, Francois P, Huyghe A et al. A global view of Staphylococcus aureus whole genome expression upon internalization in human epithelial cells. BMC Genomics 2007; 8: 171.
59. Weinrick B, Dunman PM, McAleese F et al. Effect of mild acid on gene expression in Staphylococcus aureus. J Bacteriol 2004; 186: 8407-23.
60. Papadopoulos S, Ball AM, Liewer SE et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006; 42: e108-e110.
61. Stein GE, Craig WA. Tigecycline: A critical analysis. Clin Infect Dis 2006; 43: 518-24.
62. Smith WJ, Drew RH. Telavancin: A new lipoglycopeptide for gram-positive infections. Drugs Today (Barc) 2009; 45: 159-73.
63. Brinch KS, Sandberg A, Baudoux P et al. Plectasin shows intracellular activity against Staphylococcus aureus in human THP-1 monocytes and in a mouse peritonitis model. Antimicrob Agents Chemother 2009; 53: 4801-8.
64. Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: Administration guidelines. J Antimicrob Chemother 1999; 44 Suppl A: 37-46.